Clinical and histologic response to single-dose treatment of moderate to severe psoriasis with an anti-CD80 monoclonal antibody

被引:29
|
作者
Gottlieb, AB
Lebwohl, M
Totoritis, MC
Abdulghani, AA
Shuey, SR
Romano, P
Chaudhari, U
Allen, RS
Lizambri, RG
机构
[1] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Clin Res Ctr, New Brunswick, NJ 08901 USA
[2] Mt Sinai Sch Med, New York, NY USA
[3] Idec Pharmaceut Corp, San Diego, CA USA
关键词
D O I
10.1067/mjd.2002.124698
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Pathologic T-cell activation is implicated in psoriasis progression. CD80, a costimulatory molecule involved in T-cell activation, likely plays a key role. IDEC-114, an IgG(1) anti-CD80 antibody, was evaluated for safety, pharmacokinetics, and preliminary clinical activity in this open-label, single-close, dose-escalating study in patients with moderate to severe chronic plaque psoriasis. Twenty-four patients received IDEC-114 (0.05 mg/kg, 0.25 mg/kg, 1 mg/kg, 5 mg/kg, 70 mg/kg, or 15 mg/kg). Psoriasis Area and Severity Index, Physician's Global Psoriasis Assessment, and Psoriasis Severity Scale scores improved in the highest-dose groups. Average plaque thickness and plaque CD3(+) and CD8(+) T-cell counts decreased in the 10 mg/kg dose group. Adverse events were primarily mild, transient, constitutional symptoms; the most common related events were mild asthenia (29% of patients), chills (25%), and headache (21%). The serum half-life of IDEC-114 was approximately 13 days. A single close of IDEC-114 appears to be safe and well tolerated and has promising clinical activity in psoriasis.
引用
收藏
页码:692 / 700
页数:9
相关论文
共 50 条
  • [21] Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis
    Andrea Chiricozzi
    Antonio Costanzo
    Maria Concetta Fargnoli
    Piergiorgio Malagoli
    Stefano Piaserico
    Paolo Amerio
    Giuseppe Argenziano
    Nicola Balato
    Federico Bardazzi
    Luca Bianchi
    Carlo Giovanni Carrera
    Andrea Conti
    Paolo Dapavo
    Clara De Simone
    Francesco Loconsole
    Ada Lo Schiavo
    Giovanna Malara
    Maria Letizia Musumeci
    Aurora Parodi
    Ketty Peris
    Francesca Prignano
    Franco Rongioletti
    Marina Talamonti
    Concetta Potenza
    European Journal of Dermatology, 2021, 31 : 3 - 16
  • [22] Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis
    Chiricozzi, Andrea
    Costanzo, Antonio
    Fargnoli, Maria Concetta
    Malagoli, Piergiorgio
    Piaserico, Stefano
    Amerio, Paolo
    Argenziano, Giuseppe
    Balato, Nicola
    Bardazzi, Federico
    Bianchi, Luca
    Carrera, Carlo Giovanni
    Conti, Andrea
    Dapavo, Paolo
    De Simone, Clara
    Loconsole, Francesco
    Lo Schiavo, Ada
    Malara, Giovanna
    Musumeci, Maria Letizia
    Parodi, Aurora
    Peris, Ketty
    Prignano, Francesca
    Rongioletti, Franco
    Talamonti, Marina
    Potenza, Concetta
    EUROPEAN JOURNAL OF DERMATOLOGY, 2021, 31 (01) : 3 - 16
  • [23] Treatment of severe Crohn's disease with anti-CD4 monoclonal antibody
    CanvaDelcambre, V
    Jacquot, S
    Robinet, E
    Lemann, M
    Drouet, C
    Labalette, M
    Dessaint, JP
    Bengoufa, D
    Rabian, C
    Modigliani, R
    Wijdenes, J
    Revillard, JP
    Colombel, JF
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1996, 10 (05) : 721 - 727
  • [24] EXPOSURE-RESPONSE MODELING OF LY2439821 (AN ANTI-IL-17 MONOCLONAL ANTIBODY) IN PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS.
    Tang, C.
    Choi, S.
    Satterwhite, J.
    Cameron, G.
    Banerjee, S.
    Tham, L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 : S40 - S41
  • [26] HuMax-CD4 -: A fully human monoclonal anti-CD4 antibody for the treatment of psoriasis vulgaris
    Skov, L
    Kragballe, K
    Zachariae, C
    Obitz, ER
    Holm, EA
    Jemec, GBE
    Solvsten, H
    Ibsen, HH
    Knudsen, L
    Jensen, P
    Petersen, JH
    Menné, T
    Baadsgaard, O
    ARCHIVES OF DERMATOLOGY, 2003, 139 (11) : 1433 - 1439
  • [27] Marked long-term clinical response to treatment with ustekinumab, a new monoclonal antibody for the treatment of psoriasis
    Kimball, A.
    Leonardi, C.
    Papp, K.
    Yeilding, N.
    Gordon, K.
    BRITISH JOURNAL OF DERMATOLOGY, 2008, 159 : 66 - 67
  • [28] FLIPI Score Is Applicable and Predictive of Response to Upfront Immunotherapy in CALGB 50402: Phase 11 Trial of Extended Induction Galiximab ([G] anti-CD80 monoclonal antibody) Plus Rituximab [R].
    Czuczman, Myron S.
    Leonard, John P.
    Johnson, Jeffrey L.
    Jung, Sin-Ho
    Hsi, Eric
    Byrd, John C.
    Cheson, Bruce D.
    BLOOD, 2008, 112 (11) : 369 - 369
  • [29] TREATMENT OF RHEUMATOID-ARTHRITIS WITH SINGLE DOSE OR WEEKLY PULSES OF CHIMERIC ANTI-CD4 MONOCLONAL-ANTIBODY
    CHOY, EHS
    CHIKANZA, IC
    KINGSLEY, GH
    CORRIGALL, V
    PANAYI, GS
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 1992, 36 (02) : 291 - 298
  • [30] Single dose of Anti-CD20 monoclonal antibody (rituximab) treatment in adults with refractory immune thrombocytopenic purpura (ITP).
    Tanaka, Eri
    Hayashi, Shuji
    Fujimaki, Katsumichi
    Fujita, Hiroyuki
    BLOOD, 2006, 108 (11) : 321A - 321A